Silvia D'Ippolito1, Chiara Tersigni1, Riccardo Marana2, Fiorella Di Nicuolo1, Raffaele Gaglione1, Esther Diana Rossi3, Roberta Castellani1, Giovanni Scambia1, Nicoletta Di Simone4. 1. Department of Obstetrics and Gynecology, Università Cattolica Del Sacro Cuore, A. Gemelli Universitary Hospital, Rome, Italy. 2. Department of Obstetrics and Gynecology, Università Cattolica Del Sacro Cuore, A. Gemelli Universitary Hospital, Rome, Italy; International Scientific Institute Paolo VI, ISI, Università Cattolica Del Sacro Cuore, A. Gemelli Universitary Hospital, Rome, Italy. 3. Division of Anatomic Pathology and Histology, Università Cattolica Del Sacro Cuore, A. Gemelli Universitary Hospital, Rome, Italy. 4. Department of Obstetrics and Gynecology, Università Cattolica Del Sacro Cuore, A. Gemelli Universitary Hospital, Rome, Italy. Electronic address: nicolettadisimone@rm.unicatt.it.
Abstract
OBJECTIVE: To investigate the expression of inflammosome components (NALP-3, associated speck-like protein containing a CARD [ASC]) and their activation (caspase-1, interleukin [IL]-1β, and IL-18 secretion) in the human endometrium from fertile and women with history of recurrent pregnancy loss (RPL). DESIGN: Experimental study. SETTING: University hospital. PATIENT(S): Ten fertile women (control group [CTR]) and 30 women with RPL. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Endometrial samples were collected by hysteroscopy during the putative window of implantation and evaluated for chronic endometrial inflammation by hystopathological analysis. Inflammosome expression was analysed by immunohystochemical staining (27 RPL and 10 CTR women). The expression of NALP-3 and ASC protein was quantified by Western blot (30 RPL and 10 CTR women). Caspase-1 activation and IL-1β and IL-18 secretion was quantified by ELISA (30 RPL and 10 CTR women). RESULT(S): We observed a significantly increased expression of inflammasome NALP-3 and ASC protein, an increased activation of caspase-1, and increased levels of IL-1β and IL-18 in RPL endometrium compared with CTR. CONCLUSION(S): Abnormal activation of endometrial innate immunity by means of inflammosome, stimulated by pathogen- or damage-associated molecular patterns, may represent an additional mechanism, currently not investigated, negatively interfering with endometrial receptivity. More studies are required [1] to identify the primary trigger of endometrial inflammosome activation and its clinical impact in the occurrence of RPL; and [2] to validate the inflammosome components as a novel family of endometrial biomarkers and promising therapeutic targets in RPL.
OBJECTIVE: To investigate the expression of inflammosome components (NALP-3, associated speck-like protein containing a CARD [ASC]) and their activation (caspase-1, interleukin [IL]-1β, and IL-18 secretion) in the human endometrium from fertile and women with history of recurrent pregnancy loss (RPL). DESIGN: Experimental study. SETTING: University hospital. PATIENT(S): Ten fertile women (control group [CTR]) and 30 women with RPL. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Endometrial samples were collected by hysteroscopy during the putative window of implantation and evaluated for chronic endometrial inflammation by hystopathological analysis. Inflammosome expression was analysed by immunohystochemical staining (27 RPL and 10 CTR women). The expression of NALP-3 and ASC protein was quantified by Western blot (30 RPL and 10 CTR women). Caspase-1 activation and IL-1β and IL-18 secretion was quantified by ELISA (30 RPL and 10 CTR women). RESULT(S): We observed a significantly increased expression of inflammasome NALP-3 and ASC protein, an increased activation of caspase-1, and increased levels of IL-1β and IL-18 in RPL endometrium compared with CTR. CONCLUSION(S): Abnormal activation of endometrial innate immunity by means of inflammosome, stimulated by pathogen- or damage-associated molecular patterns, may represent an additional mechanism, currently not investigated, negatively interfering with endometrial receptivity. More studies are required [1] to identify the primary trigger of endometrial inflammosome activation and its clinical impact in the occurrence of RPL; and [2] to validate the inflammosome components as a novel family of endometrial biomarkers and promising therapeutic targets in RPL.
Authors: Meredith M Stocks; Marta A Crispens; Tianbing Ding; Shilpa Mokshagundam; Kaylon L Bruner-Tran; Kevin G Osteen Journal: Reprod Sci Date: 2017-03-21 Impact factor: 3.060
Authors: Jie Yu; Sarah L Berga; Wei Zou; D Grace Yook; Joshua C Pan; Aurora Arroyo Andrade; Lijuan Zhao; Neil Sidell; Indrani C Bagchi; Milan K Bagchi; Robert N Taylor Journal: Endocrinology Date: 2017-12-01 Impact factor: 4.736
Authors: Carrie J Nobles; Pauline Mendola; Sunni L Mumford; Ashley I Naimi; Edwina H Yeung; Keewan Kim; Hyojun Park; Brian Wilcox; Robert M Silver; Neil J Perkins; Lindsey Sjaarda; Enrique F Schisterman Journal: Hypertension Date: 2018-04-02 Impact factor: 10.190
Authors: Nicoletta Di Simone; Fiorella Di Nicuolo; Riccardo Marana; Roberta Castellani; Francesco Ria; Manuela Veglia; Giovanni Scambia; Daniel Surbek; Eytan Barnea; Martin Mueller Journal: PLoS One Date: 2017-07-12 Impact factor: 3.240
Authors: Jie Yu; Sarah L Berga; Qingying Meng; Mingjing Xia; Trudy A Kohout; Marcel van Duin; Robert N Taylor Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 6.134